The Letter to the Editor by van Vught and colleagues (1) reports a lack of association of the P413L CHGB with ALS susceptibility or age of onset in a Dutch population. This report contrasts with our study that revealed an association of P413L CHGB with ALS susceptibility or age of onset, especially in cohorts from French/French-Canadian origins (2). How to explain these conflicting results? We cannot completely exclude type 1 errors in our study but it is most likely that the divergent results can be explained by population-specific effects. These combined studies reveal population differences in the frequency of P413L polymorphism and our study also pointed out a lower risk factor for ALS conferred by this polymorphism in the Swedish population. Given the high degree of genetic and clinical heterogeneity seen in ALS, these results are not too surprising. There is evidence of population differences for some of the previously identified genetic risk factors for ALS such as VEGF, ANG, DPP6, FGGY, and ITPR2 (3-5). We agree with van Vught and colleagues that independent replication of genetic association studies is crucial in understanding different mechanisms involved in human genetic diseases. This argument applies not only to a candidate gene-based approach but also to genowide-wide association studies (GWAS). The identification of genes using GWAS, in which so-called ALS patients from different populations have been pooled together, might inherently be very difficult given that many rare mutations could predispose to different ALS subtypes. To date, only three genes, namely SOD1, TARDBP, and FUS/TLS, have been robustly linked to ALS. It is noteworthy that none of these three genes were found to be associated with ALS in large GWAS datasets.
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An argument against a false positive is the transfection data in cultured cells that showed that P413L is a functional polymorphism causing defective sorting in secretory granules. More studies are needed to elucidate the physiological impact of such secretory defects. 
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